Список проголосовавших за комментарий " Acceleron Pharma: Catalyst-Rich Year Ahead: Adding XLRN to the FBR Alpha Generator (26.85)FBR adds XLRN to the FBR Alpha Generator list, as they think the stock is underappreciated and has much upside potential. XLRN has several clinical and regulatory milestones scheduled this year, with multiple Phase II and Phase III trials ongoing and new INDs expected in 2017 and 2018. Acceleron's lead pipeline candidate luspatercept is in co-development with Celgene (<strong>CELG</strong>). CELG is funding 100% of the development costs and will pay Acceleron tiered royalties upon launch in the low- to mid-20% range while XLRN retains co-promotion rights in N. Am. <strong>They believe the collaboration with XLRN is evidence that CELG has confidence in the platform, science, mgmt team, and overall businesses. Luspatercept is being studied for the treatment of anemia in ß-thalassemia and myelodysplastic syndrome (MDS). XLRN should continue to execute and expand its portfolio of innovative protein therapeutics for patients with serious diseases who have limited treatment options.</strong>"